J&J Venture Arm Invests in Delix Therapeutics' $100 Million Series C
Johnson & Johnson Innovation — JJDC Inc. and SV Health Investors' Dementia Discovery Fund led Delix Therapeutics' $100 million Series C. Delix is developing versions of psychedelic compounds without hallucinatory effects.
By Josh BeckermanJohnson & Johnson's venture capital arm invested in Delix Therapeutics, which is developing versions of psychedelic compounds without hallucinatory effects.Johnson & Johnson Innovation — JJDC Inc., and SV Health Investors' Dementia Discovery Fund led Delix's $100 million Series C f…